232 related articles for article (PubMed ID: 24398459)
21. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-
Bicker J; Fortuna A; Alves G; Soares-da-Silva P; Falcão A
Drug Metab Dispos; 2017 Dec; 45(12):1282-1291. PubMed ID: 28916530
[TBL] [Abstract][Full Text] [Related]
22. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
23. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
[TBL] [Abstract][Full Text] [Related]
24. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
25. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.
Liu X; Smith BJ; Chen C; Callegari E; Becker SL; Chen X; Cianfrogna J; Doran AC; Doran SD; Gibbs JP; Hosea N; Liu J; Nelson FR; Szewc MA; Van Deusen J
Drug Metab Dispos; 2006 Sep; 34(9):1443-7. PubMed ID: 16760229
[TBL] [Abstract][Full Text] [Related]
27. Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats.
Huang L; Li X; Roberts J; Janosky B; Lin MH
Xenobiotica; 2015; 45(6):547-55. PubMed ID: 25539457
[TBL] [Abstract][Full Text] [Related]
28. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
[TBL] [Abstract][Full Text] [Related]
29. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
[TBL] [Abstract][Full Text] [Related]
30. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
31. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
Nagaya Y; Nozaki Y; Kobayashi K; Takenaka O; Nakatani Y; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2014; 29(5):419-26. PubMed ID: 24806821
[TBL] [Abstract][Full Text] [Related]
32. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.
Ohe T; Sato M; Tanaka S; Fujino N; Hata M; Shibata Y; Kanatani A; Fukami T; Yamazaki M; Chiba M; Ishii Y
Drug Metab Dispos; 2003 Oct; 31(10):1251-4. PubMed ID: 12975334
[TBL] [Abstract][Full Text] [Related]
33. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
Uchida Y; Wakayama K; Ohtsuki S; Chiba M; Ohe T; Ishii Y; Terasaki T
J Pharmacol Exp Ther; 2014 Sep; 350(3):578-88. PubMed ID: 24947467
[TBL] [Abstract][Full Text] [Related]
34. Effect of Subchronic Intravenous Morphine Infusion and Naloxone-Precipitated Morphine Withdrawal on P-gp and Bcrp at the Rat Blood-Brain Barrier.
Chaves C; Gómez-Zepeda D; Auvity S; Menet MC; Crété D; Labat L; Remião F; Cisternino S; Declèves X
J Pharm Sci; 2016 Jan; 105(1):350-8. PubMed ID: 26554626
[TBL] [Abstract][Full Text] [Related]
35. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: a study in ex vivo lung models using chemical inhibition and genetic knockout.
Al-Jayyoussi G; Price DF; Francombe D; Taylor G; Smith MW; Morris C; Edwards CD; Eddershaw P; Gumbleton M
J Pharm Sci; 2013 Sep; 102(9):3382-94. PubMed ID: 23670704
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of blood-brain barrier and blood-cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models.
Hu HH; Bian YC; Liu Y; Sheng R; Jiang HD; Yu LS; Hu YZ; Zeng S
Int J Pharm; 2014 Jan; 460(1-2):101-7. PubMed ID: 24262988
[TBL] [Abstract][Full Text] [Related]
37. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
[TBL] [Abstract][Full Text] [Related]
38. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid.
Liu X; Van Natta K; Yeo H; Vilenski O; Weller PE; Worboys PD; Monshouwer M
Drug Metab Dispos; 2009 Apr; 37(4):787-93. PubMed ID: 19116265
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine p-glycoprotein knockout model.
Mealey KL; Greene S; Bagley R; Gay J; Tucker R; Gavin P; Schmidt K; Nelson F
Drug Metab Dispos; 2008 Jun; 36(6):1073-9. PubMed ID: 18332085
[TBL] [Abstract][Full Text] [Related]
40. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats.
Katagiri Y; Kawaguchi H; Umemura K; Tadano J; Miyawaki I; Takano M
Drug Metab Pharmacokinet; 2022 Feb; 42():100430. PubMed ID: 34896751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
